Role of Microtubule-Associated Protein 1b in Urothelial Carcinoma: Overexpression Predicts Poor Prognosis.

Tsu-Ming Chien,Steven Kuan-Hua Huang,Wei-Ming Li,Ti-Chun Chan,Ching-Chia Li,Wen-Jeng Wu,Chun-Nung Huang,Bi-Wen Yeh,Chien-Feng Li

doi:10.3390/cancers12030630

Abstract

We sought to examine the relationship between microtubule-associated proteins (MAPs) and the prognosis of urothelial carcinoma by assessing the microtubule bundle formation genes using a reappraisal transcriptome dataset of urothelial carcinoma (GSE31684). The result revealed that microtubule-associated protein 1b (MAP1B) is the most significant upregulated gene related to cancer progression. Real-time reverse-transcription polymerase chain reaction was used to measure MAP1B transcription levels in urothelial carcinoma of the upper tract (UTUC) and the bladder (UBUC). Immunohistochemistry was conducted to detect MAP1B protein expression in 340 UTUC and 295 UBUC cases. Correlations of MAP1B expression with clinicopathological status, disease-specific survival, and metastasis-free survival were completed. To assess the oncogenic functions of MAP1B, the RTCC1 and J82 cell lines were stably silenced against their endogenous MAP1B expression. Study findings indicated that MAP1B overexpression was associated with adverse clinical features and could independently predict unfavorable prognostic effects, indicating its theranostic value in urothelial carcinoma.

Highlights

Urothelial carcinoma (UC) is the most common malignancy of the urinary tract and includes UC of the urinary bladder (UBUC) and upper urinary tract (UTUC)
We found that tumors with increased microtubule-associated protein 1b (MAP1B) expression and decreased MARK4 had a more advanced primary tumor (pT) status and a higher incidence of metastatic events (Figure 1A)
MAP1Band expression significantly related to poor prognosis in we found through survival analysis that increased expression patients with urinary bladder urothelial carcinoma (UBUC) (Figure 1B)

Summary

Introduction

Urothelial carcinoma (UC) is the most common malignancy of the urinary tract and includes UC of the urinary bladder (UBUC) and upper urinary tract (UTUC). UBUC presents in most patients as a non–muscle-involved invasive disease with an estimated five-year survival rate of. Transurethral resection of the bladder and radical nephroureterectomy with bladder cuff excision remain the gold-standard treatments in UBUC and UTUC for adequate local tumor control and improved long-term survival. Despite proper surgical treatment, the mortality rate remains high [2,6,7]. Clinical prognostic factors, such as pathological tumor stage and grade, have diverse impacts in patients with identical findings; they are insufficient means for detailed risk stratification and are difficult to define before treatment [5]

Objectives

Methods

Results

Conclusion